Summary. For the first time the incidence of insulin autoantibodies and islet cell antibodies were evaluated in a prospective study from birth. Consecutive neonates (168) from mothers with Type 1 (insulin-dependent) diabetes mellitus (n = 113) and gestational diabetes (n = 55) were included at birth. To date, follow-up sera were obtained from 90 of 168 mother-child-pairs 9 months postpartum and from 39 of 168, 2 years postpartum. At birth, there was a strong correlation between the presence of antibodies in the cord blood of neonates and in maternal circulation [Type 1 diabetic mothers: 20% islet cell antibodies > 20 JDF-U (detection threshold of our islet cell antibody assay), 74 % insulin antibodies > 49 nU/ml (upper limit of normal range in sera of healthy control subjects aged 0.5 to 46 years); neonates: 21% islet cell antibodies > 20 JDF-U, 76 % insulin antibodies > 49 nU/ml; gestational diabetic mothers: 11% islet cell antibodies>20JDF-U, 18% insulin antibodies> 49 nU/ml; neonates: 13 % islet cell antibodies > 20 JDF-U, 55 % insulin antibodies > 49 nU/ml]. This supports transplacental passage of insulin antibodies and islet cell antibodies from diabetic mothers to their offspring. During follow-up, the majority of children lost antibody-positivity after birth. A few offspring, however, exhibited or developed antibodies consistently, whereby insulin autoantibodies preceded islet cell antibodies in each case (antibodypositivity: 9 months: 0 % islet cell antibody positive, 3.3 % insulin autoantibody positive; 2 years: 2.6% islet cell antibody positive, 7.7 % insulin autoantibody positive). Persisting antibody-positivity in follow-up samples of offspring of diabetic mothers was significantly correlated with older maternal age at delivery (median 38 vs 28 years, p < 0.001). It is concluded that antibodies are common in cord blood of neonates of mothers with Type i and gestational diabetes, but they normally disappear after birth. In several children, however, islet cell autoimmunity is detected at very young age.
The destruction of pancreatic beta cells in patients with Type i (insulin-dependent) diabetes mellitus is autoimmune in nature, but the initiating event and particularly the time when the diabetogenic trigger occurs in life, is not known [1] . Approximately 1 of 20 first degree relatives of patients with Type i diabetes will develop the disease and approximately 30-50% of identical twins are concordant for the disease. Little progress has been made in identifying specific environmental exposure that could provoke clinical manifestation of the genetic predisposition in one patient or prevent it in the other. Based on studies of the risk of Type 1 diabetes developing in the offspring of a parent with Type I diabetes, Warram and co-workers [2] have described a lower risk of Type 1 diabetes in children of mothers with Type i diabetes than of fathers with Type i diabetes and similar findings have been reported by investigators in Germany [3] . There was no evidence that the lower risk can be attributed to selective loss of the susceptible phenotype in perinatal deaths or spontaneous abortion [4] , but the factors responsible for that lower risk in the offspring of mothers with Type 1 diabetes remain unknown.
Islet ceil antibodies (ICA) and insulin autoantibodies (IAA) appear prior to the development of overt Type 1 diabetes [5] [6] [7] [8] [9] [10] . For purposes of studying the respective roles of immunological factors in correlation with clinical variables regarding risk or protection to diabetes, we have begun, for the first time, a prospective study of ICA and IAA in 168 offspring of diabetic mothers (n = 113 with Type 1 diabetes and n = 55 with gestational diabetes) from birth. At delivery, mean age of diabetic mothers was 28 + 4 (SD) years for Type 1, 31 _+ 5 years for GDM-A, and 31 + 5 years for GDM-BG, respectively; mean diabetes duration of Type i diabetic mothers was 12_+7 (SD) years. All insulin-treated mothers were treated with human insulin during pregnancy. Mean individual HbAI levels throughout pregnancy ranged from 5.2% to 8.4% (median 6.6%, mean + SD: 6.7 _+ 0.8 %) (normal range: less than 8 %). Mean gestation duration was 39 _+ 3 (SD) weeks (range 24-42 weeks, median 39.5 weeks). Mean neonatal weight at birth was 3414 + 642 (SD) g (range 2077-5100 g, median 3460 g).
Patients and methods

Pregnancy and birth
In addition, 17 cord blood samples from neonates of normal healthy parents were used as control samples for the determination of ICA and IAA.
Follow-up
Follow-up samples for IAA and ICA were obtained from all motherchild pairs, as soon as their children had reached 9 months and 2 years of age, respectively, except for five families who chose not to participate in the follow-up study. To date, of all 168 mother-child pairs studied at birth, 90 diabetic mothers and their offspring were followed-up for 9 months postpartum (66 with Type 1, 12 with GDM-A, and 12 with GDM-BG) and 39 were followed-up for 2 years postpartum (28 with Type 1, 6 with GDM-A, 5 with GDM-BG). On follow-up, all mothers were interviewed regarding family history of Type i and Type 2 diabetes and breast feeding.
In addition, 20 samples from non-diabetic children less than age 2 years who were hospitalized at the Children's Department (with no family history of Type i diabetes) were used as control samples for the determination of ICA and IAA.
Siblings of "neonates"
At the 2-year follow-up, all existing siblings (n = 18), who were born before 1989, i. e. before our mother, offspring study began, were also investigated for ICA and IAA.
Methods
Competitive insulin autoantibody assay (IAA). Insulin antibodies
were named IA in insulin-treated patients, because these antibodies might have been induced through exogenous insulin therapy; they were named IAA (insulin autoantibodies) in mothers and offspring who had not received any insulin injections.
Serum was tested for IA and IAA using a competitive fluid phase radiobinding assay [9, 11] . Results are expressed in nU/ml of insulin precipitated. Negative IAA levels are computational products where the counts with cold displacement are slightly greater than counts in the absence of unlabelled insulin. The range of IAA values in 103 normal control subjects (mean age 23 -+ 6 [SD] years) with no family history of diabetes was -21 nU/ml to 37 nU/ml (mean _+ SD: 5 _+ 11 nU/ml) and a cutoff of 49 nU/ml (4 SD above normal mean) was utilized as the upper limit of"normal" [12] . For the IDW International Workshop comparing IAA-assays, our assay gave an average control mean delta % binding of 0.06 ( ~ 6 nU/ml) and an SD of 0.11 ( ~ 11 nU/ml) [4 SD cutoff: 0.50 ( ~ 50 nU/ml)].
Islet cell antibody assay (ICA).
Sera were screened for ICA on sections of blood group O cryofixed human pancreas utilizing peroxidase conjugated protein A [12, 13] . The detection threshold of our ICA assay is 20 JDF-U (Juvenile Diabetes Foundation units; endpoint titre of 1:8 of the ICA standard currently being assessed by the Immunology and Diabetes Workshop).
Insulin assay. Insulin levels in cord blood of neonates were determined by a double antibody radioassay [14] . Of mothers with GDM, 11% (6 of 55) were ICA + and 18% (10 of 55) IA+ (>49nU/ml). Of their neonates 13 % (7 of 55) were ICA + and 55 % (30 of 55) had IA above 49 nU/ml (Fig.lb, left panel) . ICA were also mainly detected in those infants whose mothers were ICA positive (5 m +/n +, i m +/n-, 2 m-/n +, 47 m-/n-). Although a positive correlation of I[A]A was also found in GDM (GDM-BG: r = 0.81,p < 0.0001; GDM-A: r = 0.21, p < 0.05; Fig. 2 b, c) , some children had clearly higher titre than their mothers (i.e. three offspring of GDM-A mothers with titre of 198, 284 and 392 nU/ml, respectively). Mean IAA levels of GDM-A mothers were 20 + 3 nU/ml and of their neonates 72 _+ 15 nU/ml (p < 0.005) and mean IA levels of GDM-BG mothers were 78 + 24 nU/ml and of their neonates 132 _+ 37 nU/ml (p < 0.02).
Control neonates:
The normal range of cord blood IAA levels in normal neonates from healthy parents (although all were negative for ICA) was found to be higher than in normal children and adults during later life (cord blood in = 17]: 85 + 19 nU/ml; range 9 to 161 nU/ml; 12 of 17 above 49 nU/ml). Therefore, IAA levels of neonates of non-insulin-treated GDM-A mothers were not increased compared with IAA levels of neonates of normal parents.
Nine-months follow-up
To date, 90 mother-child-pairs (66 with Type i and 24 with GDM) have been re-tested at 9 months postpartum. On follow-up, antibody-positivity of diabetic mothers was not (Fig. I a,b , middle panel). In contrast, the majority of children had lost their antibody-positivity during their first 9 months of life, except for three infants (total: 3 of 90 = 3.3 %; of mothers with Type 1:2 of 66=3%; of mothers with GDM: i of 24 = 4 %), who were found to be IAA + at 9 months of age (IAA-level: patient B.B.2 159 nU/ml, patient M.N. 167 nU/ml, patient S. T. 89 nU/ml; Table 1 ). None (0 of 90) of the infants, however, had positive ICA ( > 20 JDF-U) at this age.
Two-years follow-up
To date, 39 mother-child-pairs (28 with Type i and 11 with GDM) have been re-tested 2years postpartum. Antibody-positivity of Type i diabetic mothers was 14 % (4 of 28) for ICA and 68 % (19 of 28) for IA and for mothers with GDM, 0 % for ICA and 27 % (3 of 11) for I[A]A (Fig. 1 a,b, right panel) . At 2 years of age, the majority of children remained antibody-negative, except three infants (total: 3 of 39 = 7.7 %; of mothers with Type 1:2 of 28 = 7 %; of mothers with GDM: i of 11 = 9 %) who were identified as having elevated antibody-titre: two infants were IAA +/ICA-(patient B.B.2: IAA 1174 nU/ml; patient S.RK.: IAA 96nU/ml) and one infant was IAA +/ICA + (patient S.T.: IAA 182 nU/ml and ICA 40 JDF-U) ( Table 1 , Fig. 1 a, b) . This implies, that since the 9-month follow-up patient B. B.2 remained IAA positive, patient S. T. remained IAA positive and converted to ICA positivity, patient S.RK. was antibody-negative before and converted to IAA positive, and patient M.N. had lost IAA positivity (Table 1) . Follow-up samples of child B. B.2 and child S. R K. were obtained recently at age 2.5 and 3.0 years, respectively. Both infants were consistently positive for IAA with increasing titre (IAA: B. B.21278 nU/ml; S. R K. 315 nU/ml) and both infants had converted to ICA-positivity at 2.5 years and 3.0 years of age, respectively (ICA: B.B.2 160 JDF-U; S.RK. 80 JDF-U) ( Table 1) .
Control children
None of 20 control children less than 2 years of age were ICA positive nor exceeded our upper limit of normal range for IAA (49 nU/ml) defined mainly with adult con-
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Fam. B. * 1960 "1988 "1990 "1989 Figure 3 and Table 3 present the history of Type 1 and Type 2 diabetes in families with AB + compared to ABoffspring. The frequency of Type 2 diabetes in second degree relatives of AB + offspring was surprisingly high on the mother's (100 % ) and on the father's side (67 %). In addition, the father of offspring S.R was identified as a Type 2 diabetic patient. The incidence of Type 2 diabetes in 2nd degree relatives of AB-offspring was lower (48 % on the mother's side and 16 % on the father's side), but the difference did not reach statistical significance. trol subjects (IAA in normal children < 2 years of age: range --4 to 34 nU/ml). In addition, none of 14 additional control subjects less than 5 years of age, who were studied by the. same IAA assay in a previous investigation, were positive for the presence of IAA (range-44.9 to 29.3 nU/ml) [15] .
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Siblings of "neonates"
In addition, all existing siblings (n = 18) of the neonates of this study were also investigated for ICA and IAA. One of 18 (5.6 % ) siblings was detected as being positive for IAA and ICA (patient B.B.I: 2.5 years of age at initial test, IAA 468 nU/ml, ICA 80 JDF-U). Patient B.B.I is the sister of patient B. B.2 (IAA + ) (see follow-up at 3 years and 3.5 years of age, Table 1 ). Patient B.B.1 developed overt Type 1 diabetes at age 3.5 years, diagnosed with an oral glucose tolerance test (2-h post prandial blood glucose: 15.6 mmol/1).
Discussion
For the first time, a prospective study from birth for the determination of IAA and ICA was performed in offspring of mothers with Type 1 diabetes and gestational diabetes. The most striking result was that antibodies to islet cell products were detected very early in life. At birth, a strong correlation between the presence of ICA and IA in the cord blood and in maternal circulation was observed. These results confirm previous findings from different groups who demonstrated positive ICA and IA in a significant proportion of neonates at birth [16] [17] [18] . It has been suggested that ICA and IA are transplacentally acquired since antibody activity was mainly observed in those infants whose mothers were also antibody-positive at the time of delivery. For the present study, however, it is noteworthy, that although levels of insulin antibodies were similar in neonates and in insulintreated mothers, fetal IAA levels did not well reflect those of non-insulin-treated diabetic mothers.
On the other hand, new evidence was also obtained that the normal range of cord blood IAA from infants of healthy parents seems to be higher than the normal range of IAA levels obtained very shortly later in life. This might be in accordance with the elevation of other blood parameters examined in cord blood samples of normal neonates which are known to return to normal values within few weeks after birth [19] .
During follow-up, the majority of children, who were antibody-positive at birth, lost their antibody-positivity within the first 9 months of life. The primary finding, however, was, that three offspring were identified as being antibody-positive at follow-up. They were all consistently Clinical characteristics and family history in antibody positive and antibody negative offspring at2 years of age Table 2 demonstrates median and mean values and range and 25th to 75th percentiles of maternal and fetal variables according to antibody-positivity (AB + ) or antibody-negativity (AB-) of the offspring. The maternal age at delivery was significantly higher in mothers with AB + than with AB-offspring (median 38 years vs 28 years, p < 0.0001). No apparent association was noted between the presence of ICA and IAA in offspring of diabetic mothers or any other variables including maternal class of diabetes, maternal diabetes duration, maternal mean HbA1, fetal gestation age, cord blood insulin levels, breast feeding, and fetal growth for this small cohort. [4] . By age 20 years, 6.1% of offspring of diabetic fathers, but only 1.3 % of offspring of diabetic mothers had the disease [4] . Similarly, the risk of children who were in utero when Type 1 diabetes developed in their mothers was described as being low [20] . With respect to these data, the prevalence of 7.7 % positivity of IAA and ICA in offspring of diabetic mothers at 2 years of age is remarkably high in the present study. In addition, one further sibling of the prospectively followed antibody-positive neonates was also detected as being persistently IAA +/ICA + from the age of 2.5 years and older and was diagnosed as having overt Type 1 diabetes at 3.5 years. Similarly, one has to assume that the other three IAA +/ICA + offspring are at very high risk of developing diabetes. The experience from previous studies with antibody screening of first degree relatives of Type 1 diabetic patients clearly demonstrated -by life table analysis -that individuals who are positive for both ICA and IAA (and especially those who have IAA levels above 150 nU/ml) have the highest rate of progression to overt diabetes (100% within five years [9] ). These high risk criteria were fulfilled in all our positive offspring at the most recent follow-up.
There may be several explanations for the high prevalence of antibody-positivity in the offspring of our coReferences hort: 1) the incidence of Type i diabetes is rising in offspring of diabetic mothers; 2) the incidence is different in the population we studied; 3) the high prevalence of ICA and IAA is an artefact through the relatively small number of offspring followed up to 2 years of age. On the other hand, the figure found in our study might even be an underestimate and there will be additional children who become antibody-positive later in life.
In the present investigation, antibody-positivity in offspring of diabetic mothers was significantly correlated with older maternal age at delivery. This is in contrast to findings by Warram and coworkers [21] , who reported that offspring born at maternal age above 25 years had a significantly lower risk than those born at younger maternal ages, whereas Bleich and coworkers [22] described a higher risk for offspring of diabetic mothers with long duration of diabetes, especially when the mother acquired diabetes before age 12. The present study neither indicated a correlation between the presence of antibodies and maternal diabetes duration nor age of maternal diabetes onset. In addition, no apparent association was noted between the presence of ICA and IAA in offspring of diabetic mothers and any other clinical variables including maternal class of diabetes, maternal mean HbA1, fetal gestational age, cord blood insulin levels, fetal growth, and breast feeding (some associations, however, may become significant, when larger numbers of offspring are studied). It was reported that exclusive breast feeding with delayed exposure to infant formula diet based on 407 cow's milk significantly reduced the risk of diabetes [23, 24] . In this context, the time of breast feeding was remarkably low in the ICA +/IAA + offspring (median 0.5 months) of the present study, yet not significantly different compared with the antibody-negative group (median 2 months).
The frequency of Type 2 diabetes in second degree relatives was high in ICA +/IAA + infants compared to antibody-negative infants, but the difference did not reach statistical significance. This observation might be in line with our previous survey, in which a striking frequency of Type 2 diabetes among second degree relatives of Type 1 diabetic patients was demonstrated (47% of Type 1 families vs 19 % of control families were found to have second degree relatives with Type 2 diabetes, p = 0.0003), although it has been suggested that Type 1 and Type 2 diabetes are two distinct entities based on a different genetic background [25] .
In summary we conclude that insulin autoantibodies and islet cell antibodies are acquired at very young age in offspring of mothers with Type 1 diabetes and gestational diabetes. Antibody screening at the age of 2 years might be a very useful tool to detect individuals at high-risk for the development of childhood Type 1 diabetes.
